Trial · NCT02029040
Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
NCT02029040, Not applicable, Completed, University of Texas Southwestern Medical Center; results first posted 2019-01-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis. Trials, record NCT02029040. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02029040
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
- NCT number
- NCT02029040
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 52 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Acute Bronchiolitis
- Interventions
- 3% Hypertonic Saline, 0.9 % normal saline
- First posted
- 2014-01-07
- Last updated
- 2019-01-25
- Results first posted
- 2019-01-25
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Respiratory Assessment Change Score (RACS) | 5-15 minutes | The primary outcome variable is the Respiratory Assessment Change Score (RACS) which is a sum of the change in the Respiratory Distress Assessment Instrument (RDAI)score plus a standardized score for the change in respiratory rate; the change in respiratory rate is assigned 1 point per each 10% change in the respiratory rate.The RDAI score is the sum of the row scores, with total range 0 to 17; higher scores indicate more severe disease. |
| Secondary | Rate of Hospitalizations | 24 hours |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Respiratory Assessment Change Score (RACS) | 5-15 minutes | score on a scale | MEAN | |
| SECONDARY | Rate of Hospitalizations | 24 hours | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Respiratory Assessment Change Score (RACS) | 3% Hypertonic Saline Group | 1.68 | 95% Confidence Interval 0.52 to 2.84 | score on a scale | |
| Respiratory Assessment Change Score (RACS) | 0.9% Normal Saline Group | 1.70 | 95% Confidence Interval 0.70 to 2.70 | score on a scale | |
| Rate of Hospitalizations | 3% Hypertonic Saline Group | 9 | participants | ||
| Rate of Hospitalizations | 0.9% Normal Saline Group | 11 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 0.9% Normal Saline Group | 27 | |
| Overall Study | STARTED | Hypertonic Saline Group | 25 | |
| Overall Study | COMPLETED | 0.9% Normal Saline Group | 27 | |
| Overall Study | COMPLETED | Hypertonic Saline Group | 25 | |
| Overall Study | NOT COMPLETED | 0.9% Normal Saline Group | 0 | |
| Overall Study | NOT COMPLETED | Hypertonic Saline Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 3% Hypertonic Saline Group | 0 | 25 |
| Total, all-cause mortality | 0.9% Normal Saline Group | 0 | 27 |
| Total, other adverse events | 3% Hypertonic Saline Group | 0 | 25 |
| Total, other adverse events | 0.9% Normal Saline Group | 0 | 27 |
| Total, serious adverse events | 3% Hypertonic Saline Group | 0 | 25 |
| Total, serious adverse events | 0.9% Normal Saline Group | 0 | 27 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 3% Hypertonic Saline Group vs 0.9% Normal Saline Group: Rate of Hospitalizations | Trial comparisons |
| 3% Hypertonic Saline Group vs 0.9% Normal Saline Group: deaths from any cause | Trial comparisons |
| 3% Hypertonic Saline Group vs 0.9% Normal Saline Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02029040
GET https://conductscience.org/api/trials/v1/NCT02029040/registered